Putative Astroglial Dysfunction in Schizophrenia: A Meta-Analysis of ¹H-MRS Studies of Medial Prefrontal Myo-Inositol

Tushar Kanti Das¹,²,³, Avyarthana Dey¹,², Priyadharshini Sabesan¹, Alborz Javadzadeh¹, Jean Théberge³,⁴, Joaquim Radua⁵ and Lena Palaniyappan¹,²,³,⁴*

¹ Department of Psychiatry, University of Western Ontario, London, ON, Canada. ²Robarts Research Institute, London, ON, Canada. ³Lawson Health Research Institute, London, ON, Canada. ⁴Department of Medical Biophysics, University of Western Ontario, London, ON, Canada. ⁵FIDMAG Germanes Hospitalàries, CIBERSAM, Sant Boi de Llobregat & Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Background: Several lines of evidence support a role for astroglial pathology in schizophrenia. Myo-inositol is particularly abundant in astroglia. Many small sized studies have reported on myo-inositol concentration in schizophrenia, but to date these have not been pooled to estimate a collective effect size.

Methods: We reviewed all proton magnetic resonance spectroscopy (1H-MRS) studies reporting myo-inositol values for patients satisfying DSM or ICD based criteria for schizophrenia in comparison to a healthy controls group in the medial prefrontal cortex published until February 2018. A random-effects model was used to calculate the pooled effect size using metafor package. A meta-regression analysis of moderator variables was also undertaken.

Results: The literature search identified 19 studies published with a total sample size of 585 controls, 561 patients with schizophrenia. Patients with schizophrenia had significantly reduced medial prefrontal myo-inositol compared to controls (RFX standardized mean difference = 0.19, 95% CI [0.05–0.32], z = 2.72, p = 0.0067; heterogeneity p = 0.09). Studies with more female patients reported more notable schizophrenia-related reduction in myo-inositol (z = 2.53, p = 0.011).

Discussion: We report a small, but significant reduction in myo-inositol concentration in the medial prefrontal cortex in schizophrenia. The size of the reported effect indicates that the biological pathways affecting the astroglia are likely to operate only in a subset of patients with schizophrenia. MRS myo-inositol could be a useful tool to stratify and investigate such patients.

Keywords: myo-inositol, astroglia, schizophrenia, inflammation, spectroscopy

INTRODUCTION

A role for astroglial pathology has been long suspected in schizophrenia (1–3). Astrocytes are critical for reducing oxidative stress and restoring redox balance in the brain, thus preventing neurotoxicity (4, 5). Astrocytes enable the crucial glutamate-glutamine cycle that helps clear extracellular glutamate from synaptic space as well as reduce the deleterious cellular ammonia...
content (6, 7). In addition, two crucial indicators of neuronal connectivity—synaptic maintenance and myelination—appear to rely on astrocytic guidance (8–10). Thus, abnormalities in astrocytic function can produce neuronal dysconnectivity as well as glutamatergic abnormalities that are known to occur in schizophrenia (11). Indeed, converging genetic and molecular evidence now supports the case for a primary role of astroglial dysfunction in schizophrenia (10, 12).

In vivo imaging of astrocytic integrity holds promise in clarifying the nature of its dysfunction in schizophrenia. $^1$H-MRS does not specifically differentiate between brain cell types; nevertheless, given that myo-inositol is particularly abundant in astroglia rather than the neurons and other cells, it can be considered an astroglial marker (13, 14). The MRS measure of myo-inositol predominantly reflects astrocytic intracellular compartment, where it has osmotic functions (15, 16). An increase in MRS myo-inositol resonance relates to markers of astroglial activation (17, 18), associated with gliosis (19, 20), and occurs in response to brain injury (21, 22), thus reflecting an inflammatory response. On the other hand, myo-inositol also has an important role as an intracellular second messenger in calcium mediated glutamatergic signaling (23). Reduced myo-inositol resonance may relate to astroglial dysfunction and consequently, aberrant extracellular glutamate clearance from synaptic space. Thus, low levels of myo-inositol may in turn facilitate excitotoxic damage and local inflammatory processes that are currently subjects of investigation in the pathophysiology of schizophrenia (1).

Many small sized studies have reported on myo-inositol concentration in schizophrenia, but to date these have not been pooled to estimate a collective effect size (24). Examining the state of myo-inositol abnormalities will aid in our understanding of the role of astroglial cells in schizophrenia. We reviewed MRS studies reporting myo-inositol resonance in schizophrenia and conducted a meta-analysis to synthesize the nature of myo-inositol abnormalities in the medial prefrontal cortex of patients with schizophrenia. We focussed on the medial prefrontal cortex as most MRS studies in schizophrenia have placed voxels in this brain region (24).

**METHODS**

**Search Process**

We followed the guidelines set out by the consensus statement from PRISMA group (25). Our literature search started with the MEDLINE electronic database to identify journal articles published until 28 February 2018. We used the following Medical Subject Headings and freeform search terms: (schizophrenia OR schizo* OR psychos* OR psychot*) AND (“$^1$H-MRS” OR “$^1$NMRS” OR “1HMRS” OR “MRS” OR “Magnetic resonance spectroscopy” OR “Spectroscopy” OR “proton magnetic resonance spectroscopy”) AND (“myo-inositol” OR “inositol” OR “myo-inositol”). We noted that in many reports, myo-inositol was reported as a secondary measure, and not included in keywords or abstracts. As a result, we used the terms (“glutathione” OR “NAA” OR “n-acetyl aspartate” OR “glutamine” OR “GSH” OR “neurometabolic” OR “Glutamate” OR “Glu” OR “GABA” OR “Lactate” OR “creatinine”) instead of the 3 terms denoting myo-inositol in order to identify all eligible studies. We attempted to contact authors whenever the individual studies indicated that myo-inositol resonance of adequate quality was measured in the brain region of interest (see below) but when the data was not published. We also undertook a manual search of reference lists of review articles and eligible full text articles. Third, we repeated the search with Google Scholar to identify journal articles that were not indexed on MEDLINE. Finally, we also searched the citation records of Google Scholar for all identified full text articles in order to locate in press articles that are not yet indexed. Two authors (AD and PS) undertook independent searches using the inclusion and exclusion criteria without any exchange of notes.

**Inclusion/Exclusion Criteria**

Peer-reviewed articles in English language reporting myo-inositol concentrations in the brain in patients with schizophrenia or schizoaffective disorder in comparison with a healthy control group were included. We did not include studies that only report on patients with bipolar disorder or depression related psychosis. We selected studies where the largest proportion of MRS voxel was placed on the medial prefrontal cortex, anterior to the posterior commissure, as per the cingulate boundaries defined by Vogt et al. (26). This ensured that both caudal and rostral ACC placements were included, but posterior cingulate voxels were excluded. In line with Egerton et al. (27), we will use the term medial frontal cortex (mFC) to describe this region of distributed voxel placement.

We excluded $^1$H-MRS studies that reported within-subject changes in myo-inositol without the required group comparison contrast and studies that excluded adult samples of age >16. If a single study was reported as 2 samples, the largest sample was included. In case of partial overlap, both studies were included with weighting based only on the non-overlapping sample for the smaller study (28, 29). We also excluded studies where no information was available on voxel placement (30) or when study-specific Cramer-Rao Lower Bound (a measure of MRS signal quality and reliability) was exceeded for myo-inositol signal (31).

We extracted the study-specific mean and standard deviation of $^1$H-MRS myo-inositol concentration for the control and patient groups. As the meta-analysis was based on effect size from group differences, we included absolute as well as ratio measures of myo-inositol concentrations, as long as both patients and controls in a dataset had identical metrics reported. When a study reported on more than 1 demographically stratified patient group, all contrasts were included in the meta-analysis (29); when groups were stratified according to clinical characteristics (e.g., treatment response) but compared against a single control group, the contrasts were combined to form a single dataset (weighted mean and pooled SD for a single patient group) (32). When voxels were split into 2 hemispheres, average values were computed (mean value from the 2 hemispheres and...
pooled SD). We contacted authors when these values were not reported or if moderator variables for meta-regression were not available.

Meta-analysis was conducted using the metafor package of R CRAN (33). We used a random-effects model to calculate the pooled effect size, with 95% confidence limits. This approach enables more robust inferences when there is a notable heterogeneity among individual studies. We assessed heterogeneity using $I^2$ statistics for quantification and Cochran’s $Q$ for statistical significance test. Potential publication bias was quantified using Egger’s test. Sensitivity testing was carried out using a jack-knife approach. During each of the iterations of this leave-one-out jack-knife testing, one study was left out and the meta-analytical estimate for (n-1) studies was recalculated. Meta-regression analyses were undertaken to investigate the effect of (1) age (based on mean age of patients) (2) gender (based on % female patients) (3) medication status (based on % unmedicated patients) (4) scanner strength (in Tesla) and (5) duration of illness (based on mean years of illness).

### RESULTS

#### Search Results

The literature search identified 19 studies (one with 2 eligible contrasts (29)), published between 2002 and 2018, with a total of 561 patients and 585 controls (PRISMA flow diagram presented Figure 1) (29, 32, 34–49). The sample sizes ranged from 10 to 75 for controls and 9–72 for patients (Table 1). Mean illness duration varied between 0.49 and 27.4 years.

The voxel placement of individual studies is shown in Figure 2. MRS parameters for individual studies are shown in Table 2.

#### Meta-Analysis Results

The estimate of heterogeneity had a trend level statistical significance ($I^2 = 14.61\%;$ Cochran’s $Q = 27.64, p = 0.09$) among the 20 datasets eligible for analysis. Random effects analysis revealed reduced myo-inositol content in patients...
TABLE 1 | Clinical and demographic features of studies included in the meta-analysis.

| Study         | Year | Number of patients/controls | Patients mean mI (SD) | Controls mean mI (SD) | % Female patients | Age patient Mean (SD) in years | Age controls Mean (SD) in years | Unmedicated patients in % | Illness duration Mean (SD) in years |
|---------------|------|-----------------------------|-----------------------|-----------------------|-------------------|-------------------------------|------------------------------|------------------------------|-------------------------------|
| Theberge 2002 | 20/20| 8.82 (3.92)                 | 8.72 (2.71)           | 35.00                 | 23.50 (7.20)      | 25.52 (7.29)                 | 100                          | 1.75 (2.00)                  |
| Delamillieure 2002 | 17/14| 0.63 (0.19)                 | 0.66 (0.13)           | 17.65                 | 31.25 (6.09)      | 30.14 (6.39)                 | 29.41                        | 8.42 (5.45)                 |
| Theberge 2003  | 21/21| 9.73 (3.1)                  | 8.74 (3.38)           | 4.76                  | 37.10 (10.60)     | 33.30 (11.73)                | 0                            | 15.6 (8.92)                 |
| Yasukawa 2005  | 15/20| 0.98 (0.28)                 | 1.29 (0.24)           | 46.67                 | 32 (4.9)          | 36.1 (6.8)                   | 13.33                        | 1.7 (2.10)                  |
| Ongur 2008     | 17/21| 0.92 (0.33)                 | 1.09 (0.32)           | 41.18                 | 41.8 (9.8)        | 34.3 (10)                    | 0                            | NA                          |
| Tayoshi 2009   | 30/25| 6.73 (2.2)                  | 8.22 (2.35)           | 53.33                 | 33.8 (9.5)        | 34.9 (10.7)                  | 0                            | 10.3 (8.7)                  |
| Delamillieure 2002 | 17/14| 0.63 (0.19)                 | 0.66 (0.13)           | 33.33                 | 39 (10.8)         | 36.3 (9.8)                   | 13.33                        | 21.1 (7.3)                  |
| Shirayama 2010 | 19/18| 5.7 (0.68)                  | 5.55 (0.72)           | 36.84                 | 30.5 (4.9)        | 31.4 (8.4)                   | 5.26                         | 7.3 (5.2)                   |
| Lutkenhoff 2010 | 9/21| 7.90 (1.73)                  | 8.26 (2.65)           | 44.44                 | 48.8 (11.5)       | 55.7 (3.8)                   | 0                            | 27.4 (11.1)                 |
| Bustillo 2014  | 72/75| 10.97 (5.47)                | 11.03 (4.96)          | 15.28                 | 36.43 (14.25)     | 35.04 (12.17)                | 3.7                          | 15.9 (5.5)                  |
| Demjaha 2014   | 14/10| 6.88 (1.66)                 | 6.39 (1.07)           | 54.17                 | 44.8 (10.9)       | 44.2 (8.9)                   | 0                            | 16.2 (9.4)                  |
| Chiappelli 2015| 59/69| 6.84 (0.84)                 | 6.94 (0.60)           | 30.51                 | 37.1 (10.6)       | 33.3 (11.73)                 | 5.08                         | NA                          |
| Brandt 2016    | 24/24| 6.36 (1.34)                 | 6.69 (0.88)           | 20.83                 | 37.5 (16.7)       | 36.6 (14.6)                  | 0.00                         | NA                          |
| Rowland 2016a  | 45/53| 6.8 (0.9)                   | 6.9 (0.60)            | 35.56                 | 37.7 (12.8)       | 37.1 (13.1)                  | 8.9                          | 14.7 (12.1)                 |
| Rowland 2016b  | 27/29| 5.8 (0.64)                  | 5.80 (0.42)           | 37.04                 | 34.4 (13.1)       | 29.7 (9.4)                   | 18.52                        | 13.1 (12.1)                 |
| Chiu 2017      | 19/14| 5.13 (2.65)                 | 7.71 (1.63)           | 42.11                 | 29.11 (6.68)      | 27.71 (5.88)                 | 0                            | 1.47 (1.23)                 |
| Taylor 2017    | 16/18| 8.4 (1.3)                   | 8.00 (0.80)           | 18.75                 | 22.7 (2.9)        | 23.9 (4.6)                   | 6.06                         | 2.46 (1.31)                 |
| Wittenburg (young) 2017 | 48/54| 6.6 (0.7)                   | 6.72 (0.50)           | 29.17                 | 25.2 (4.5)        | 25.2 (4.8)                   | 8.33                         | 6.1 (5.8)                   |
| Wittenburg (older) 2017 | 47/39| 6.82 (0.9)                  | 7.00 (0.80)           | 44.68                 | 49.5 (5.4)        | 51.2 (5.7)                   | 4.26                         | 25.4 (9.3)                  |
| Reid 2018      | 21/21| 4.88 (0.47)                 | 5.03 (0.50)           | 23.81                 | 23.2 (4.4)        | 23.5 (4.5)                   | 4.76                         | 0.49 (0.86)                 |

mI, myo-inositol (absolute or ratio measure of concentration).

FIGURE 2 | Voxel locations in medial frontal cortex for 1H-MRS studies of myo-inositol included in this meta-analysis. Studies from which a sagittal view of the MRS voxel could not be obtained are not included in this illustration.

with schizophrenia compared to healthy controls (effect estimate = 0.19, 95% CI [0.05–0.32], z = 2.72, p = 0.0067). These results are displayed in the forest plot Figure 3.

Sensitivity/Bias Analysis
All the 16 iterations of the leave-one out analyses were statistically significant, indicating that the meta-analytical estimates were reliable and not influenced by any single study. Egger’s test for funnel plot asymmetry (Figure 4) was not statistically significant (t = 0.77, p = 0.45), indicating low probability of publication bias.

Meta-Regression Analysis
There was a statistically significant moderator effect of the percentage of female patients included in the samples in the effect size for myo-inositol (z = 2.53, p = 0.011). With this moderator, heterogeneity significantly decreased (Cochran’s Q = 21.2, p = 0.27). Specifically, studies with more female patients were more likely to report reduced myo-inositol concentrations in patients compared to controls (Figure 5). We did not find any statistically significant moderator effect of the proportion of unmedicated patients (z = −0.60, p = 0.55), scanner strength (z = −1.21, p = 0.22), echo time (z = 1.59, p = 0.11), repetition time (z = 0.13, p = 0.9), age of patients (z = −0.05, p = 0.95), and duration of illness (z = −0.94, p = 0.34).

DISCUSSION
The main finding from this meta-analysis is the observation of a small, but statistically significant reduction in myo-inositol concentration in the medial frontal cortex in schizophrenia. There is a notable heterogeneity across MRS studies; a substantial
proportion of this heterogeneity is explained by the sex distribution in individual studies. In studies with higher number of female patients, the myo-inositol reduction is much more pronounced. We found no evidence of publication bias, and the meta-analytic estimates were sensitive to removal of any of the individual studies. These results indicate that myo-inositol reduction in medial frontal cortex occurs in some patients with schizophrenia, especially in a subset that is more likely to include female patients.

To our knowledge, this is the first meta-analysis of MRS myo-inositol studies in schizophrenia. Post-mortem studies in schizophrenia indicate a reduction in frontal myo-inositol (50) as well as reduced glial cell count (51), of 32–35% in layer 5 (52, 53) and 20% in layer 6 of the prefrontal cortex (54), though contradicting results indicating normal (55, 56) or increased glial cell counts also exist (57, 58). In this context, reduced myo-inositol resonance reported in our meta-analysis, when taken together with reduced glutamate levels reported in established cases of schizophrenia (59), may reflect deficits in astrocyte activation and recruitment [as proposed in (21)], rather than an actual reduction in the cell count.

Our meta-regression analysis indicates that studies with female subjects are more likely to report lower myo-inositol resonance among patients. An association between sex and myo-inositol has not been reported so far in schizophrenia (36, 46). Interestingly, Chiappelli et al. reported that depressive symptoms, rather than sex, are associated with lower myoinositol in schizophrenia (36). Both reductions in myo-inositol (60) and glial loss (61) in the medial prefrontal cortex are reported in depressive disorder. Given that one-third of patients with schizophrenia require antidepressant treatments (62), it is possible that myoinositol reduction is prominent in a subgroup of patients prone to depression. We were not able to test this notion, as except for Chiappelli et al. other MRS studies have not reported on the distribution of affective symptom severity among patients with schizophrenia. Nevertheless, it is worth noting that depression is much more common among women, than men with schizophrenia (63). Sex-specific epigenetic differences have been noted in the enzymes that regulate myo-inositol turnover in rat tissues (64). Importantly, astrocytes exhibit sexual dimorphism during development (65) and in their response to inflammation in later life (66, 67). Further investigations in larger samples of female human subjects, and in patients with and without affective symptoms are warranted.

Meta-analyses of medial prefrontal MRS studies suggest that glutamate (68), N-acetyl aspartate levels (69) are reduced in schizophrenia indicating possible dendritic reduction (70), while no consistent changes are noted in GABA concentration (27) or pH levels (71). Glutamate levels are higher during early stages of schizophrenia, but appear reduced in older cohorts with more established illness (68). We did not observe any age-or illness duration related effects on myo-inositol reduction, suggesting that astrogial dysfunction could be an invariant feature of schizophrenia, possibly contributing to the observed course of glutamatergic abnormalities. Preclinical studies suggest that at excitotoxic levels of glutamatergic signaling, inositol

---

**TABLE 2 | MRS parameters of individual studies.**

| Study                | Year | Field strength (T) | MRS fitting model | Voxel size/volume (cm x cm x cm) or cc | MRS sequences | TE/TR (ms) |
|----------------------|------|--------------------|-------------------|---------------------------------------|---------------|------------|
| Theberge             | 2002 | 4                  | fitMAN            | 1.0 x 1.5 x 1.0                       | STEAM         | 20/2,000   |
| Delamilleure         | 2002 | 1.5                | In-house analysis | 3 x 1.5 x 2.5                         | STEAM         | 30/1,500   |
| Theberge             | 2003 | 4                  | fitMAN            | 1.0 x 1.5 x 1.0                       | STEAM         | 20/2,000   |
| Yasukawa             | 2005 | 1.5                | In-house analysis | 1.8 cc                                | PRESS         | 30/1,500   |
| Ongur                | 2008 | 4                  | LCM Model         | 2.0 x 2.0 x 2.0                       | PRESS         | 48/2,000   |
| Tayoshi              | 2009 | 3                  | LCM Model         | 2.0 x 2.0 x 2.0                       | PRESS         | 30/3,000   |
| Shirayama            | 2010 | 4                  | LCM Model         | 2.3 x 2.2 x 2.3                       | MEGA-PRESS    | 30/5,000   |
| Lukenhoff            | 2010 | 3                  | LCM Model         | 2.0 x 2.0 x 2.0                       | PRESS         | 68/2,000   |
| Bustillo             | 2014 | 3                  | LCM Model         | 2.0 x 2.0 x 2.0                       | PRESS         | 40/1,500   |
| Demjaha              | 2014 | 3                  | LCM Model         | 2.0 x 2.0 x 2.0                       | PRESS         | 30/3,000   |
| Chiappelli           | 2015 | 3                  | LCM Model         | 4.0 x 3.0 x 2.0                       | PR-STEAM      | 6.5/2,000  |
| Brandt               | 2016 | 7                  | LCM Model         | 3.0 x 2.0 x 1.2                       | STEAM         | 28/3,000   |
| Rowland              | 2016a| 3                  | LCM Model, GannetFit | 4.0 x 3.0 x 2.0               | PR-STEAM      | 14/3,000   |
| Rowland              | 2016b| 7                  | LCM Model         | 4.0 x 3.0 x 2.0                       | STEAM         | 6.5/2,000  |
| Chiu                 | 2017 | 3                  | GannetFit         | 3.0 x 3.0 x 3.0                       | MEGA-PRESS    | 68/2,000   |
| Taylor               | 2017 | 7                  | fitMAN            | 2.0 x 2.0 x 2.0                       | STEAM         | 15/3,000   |
| Wittenburg (young)   | 2017 | 3                  | In house analysis | 3.0 x 4.0 x 2.0                       | PR-STEAM      | 6.5/2,000  |
| Wittenburg (older)   | 2017 | 3                  | In house analysis | 3.0 x 4.0 x 2.0                       | PR-STEAM      | 6.5/2,000  |
| Reid                 | 2018 | 7                  | LCM Model         | 2.7 x 2.0 x 1.0                       | STEAM         | 5/10,000   |

LCModel, Linear Combination Model; STEAM, STimulated Echo Acquisition Mode; PRESS, Point RESolved Spectroscopic Sequence; MEGA-PRESS, MEshcher-GArwood Point RESolved Spectroscopy; PR-STEAM, Phase Rotation STimulated Echo Acquisition Mode; TE/TR, Echo Time/Repetition Time.
turnover could be notably reduced. In this context, the putative dysfunction of synaptic transmission in schizophrenia could share a common origin, simultaneously affecting the neuron-astroglia network. Similar to NAA, myo-inositol also reflects cellular membrane integrity. Thus a combined NAA and myo-inositol changes could reflect the status of dendritic spine development or loss, as shown in preclinical studies (72). While the existing MRS literature cannot be taken as conclusive due to several technical limitations (as highlighted in the meta-analyses cited above), the observations to date make a compelling case to consider astrocytic dysfunction in further detail in schizophrenia.

There are several caveats that need to be considered when interpreting the results reported here. We limited our analysis to medial prefrontal cortex, as the number of studies examining other brain regions is limited and voxel placements are more diverse. As a result, the observed myo-inositol reduction may not be generalizable to other brain regions. In fact, an increase in MRS myo-inositol signal has been reported in regions such as basal ganglia (73) and parietal lobe (74) in patients with schizophrenia, while a reduction occurs in medial temporal white matter (75). Secondly, mood stabilizers acutely deplete inositol levels (76). None of the included studies reported on the use of mood stabilizer drugs in the patient samples. The effect of antipsychotics on myo-inositol concentration is hitherto unknown. Antipsychotics can reduce astrocyte count, and thus contribute to reduced myo-inositol concentration (77), though regional differences can be expected from existing data (78). We did not find any systematic association between either unmedicated patient numbers or duration of illness (which often relates also to cumulative antipsychotic exposure in clinical settings) to the reported effect sizes. Furthermore, both schizophrenia and antipsychotics can affect metabolite relaxation rates (mostly T1, but likely also T2) (79–81). Therefore, the choice of acquisition technique, at a given field strength, could affect the ability to detect a difference between patients and controls. Nevertheless, we did not observe any linear relationship

FIGURE 3 | Forest plot of MRS myo-inositol studies comparing schizophrenia vs. healthy controls.

FIGURE 4 | Funnel plot of MRS myo-inositol studies comparing schizophrenia vs. healthy controls.
between echo time, scanner strength, repetition time and effect sizes reported in individual studies. We noted several studies where MRS sequences were suitable to extract myo-inositol concentrations alongside other metabolites, but myo-inositol levels were not measured or reported. Though our estimate of publication bias was low, it is likely that MRS myo-inositol concentration is largely underreported in the literature. Finally, we did not include analysis that primarily contrasted bipolar disorder or depression with psychosis with healthy controls or patients with schizophrenia. Thus, the observed changes in myo-inositol cannot be taken to be specific for schizophrenia.

Prenatal exposure to maternal immune activation (MIA) reduces cingulate cortex myo-inositol in mice, which in turn relates to physiological markers of schizophrenia phenotype such as deficits in pre-pulse inhibition and reduced glutamic acid decarboxylase (GAD67) levels (82). These changes were reversed when the offspring were exposed to a n-3 polyunsaturated fatty acid (PUFA) enriched post-weaning diet (82). Consistent with this observation, healthy human subjects who have reduced omega-3 fatty acid profile (measured from erythrocytes), show reduced medial prefrontal myo-inositol and exhibit slower reaction times in a continuous performance task (83). We speculate that these observations, considered alongside the reported reduction in myo-inositol levels in schizophrenia, may indicate a specific developmental perturbation. It is worth noting that dietary replacements may not have the same intended effect across disorders; for example, in major depressive disorder where myo-inositol level is reduced, inositol supplementation appears to be beneficial (84, 85), though similar effects have not been observed in schizophrenia (86, 87). Studies that investigate the effect of dietary interventions on brain myo-inositol levels in specific diagnostic subgroups are warranted to further understand the translational potential of such approaches.

It is important to note that both increased (21, 22) and reduced (88–91) brain myo-inositol levels have been noted in various inflammatory states. Thus, the reduced myo-inositol level noted in schizophrenia does not contradict the role of neuroinflammation in this illness. In fact, this observation adds an important clarification that the inflammatory changes observed to date may be secondary to a permissive astrocytic environment, whereby reduced myo-inositol levels in astrocytes facilitate osmotic damage, as well as glutamatergic excess. Without longitudinal data that tracks pre-psychotic and post-psychotic changes in same individuals, this notion of primary astrocytic dysfunction should be considered to be merely speculative.

In summary, in patients with schizophrenia, a small but statistically significant reduction in medial prefrontal myo-inositol resonance is observable. The size of the reported effect indicates that the biological pathways affecting the myo-inositol system are likely to operate only in a subset of patients with schizophrenia. In this regard, MRS myo-inositol could be a useful tool to parse heterogeneity as well as to explore treatment stratification in schizophrenia. Furthermore, combining MRS myo-inositol measurement with in-vivo probes of astroglial function (e.g., PET ligands selective for the astrocytic imidazoline binding sites (92)) could take this investigation further in the near future.

**AUTHOR CONTRIBUTIONS**

LP conceived, designed, supervised the analysis, and wrote the draft manuscript. TD undertook the statistical analysis, prepared figures and tables, and contributed to writing the manuscript. JR undertook the statistical analysis and contributed to writing the manuscript. AD and AJ undertook literature search, prepared figures/tables, and contributed to writing the
manuscript. PS undertook literature search, verified extracted data, and contributed to writing the manuscript. JT contributed to the conception of the review and contributed to writing the manuscript.

**FUNDING**

This work was funded by the Canadian Institute of Health Research (Foundation Grant 375104 to LP), Bucke Family Fund (LP and PS), and the Academic Medical Organization of South Western Ontario (LP). This work was also supported by Miguel Servet western contract from the Carlos III Health Institute (Spain) to JR (CP14/00041).

**ACKNOWLEDGMENTS**

We acknowledge the authors who provided data on request: Dr. Juan Bustillo.

**REFERENCES**

1. Bernstein H-G, Steiner J, Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. *Exp Rev Neurother.* (2009) 9:1059–71. doi: 10.1086/ern.09.59
2. Harrison PJ. Neuropathology of schizophrenia. *Psychiatry* (2005) 4:18–21. doi: 10.1038/syst.2005.4.10.18
3. Schnieder TP, Dwork AJ. Searching for neuropathology: gliosis in schizophrenia. * Biol Psychiat.* (2011) 69:134–9. doi: 10.1016/j.biopsych.2010.08.027
4. Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. *Cell Metab.* (2011) 14:724–38. doi: 10.1016/j.cmet.2011.08.016
5. Dringen R, Pfeiffer B, Hamprecht B. Synthesis of the antioxidan t precursor for neuronal glutathione. *J Neurosci.* (1999) 19:562–9. doi: 10.1523/JNEUROSCI.19-02-00562.1999
6. Rose CF, Verkhratsky A, Parpura V. Astrocyte glutamine synthetase: pivotal in health and disease. * Biochem Soc Trans.* (2013) 41:1518–24. doi: 10.1042/BST20130237
7. Schousboe A, Scarfidi S, Bak LK, Waagepetersen HS, McKenna MC. Glutamate metabolism in the brain focusing on astrocytes. *Adv Neurol.* (2014) 11:13–30. doi: 10.1097/01.nrl.0000493564.22128.11
8. Belanger M, Magistretti PJ. The role of astroglia in neuroprotection. *Dialog Clin Neurol.* (2009) 11:281–95.
9. Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. *Nat Rev Neurosci.* (2005) 6:626–40. doi: 10.1038/nrn1722
10. Windrem MS, Osipovitch M, Liu Z, Bates J, Chandler-Militello D, Zou L, et al. Human iPSC glial mouse chimeras reveal glial contributions to schizophrenia. *Cell Stem Cell* (2017) 21:195–208.e6. doi: 10.1016/j.stem.2017.06.012
11. Xia M, Abazyan S, Jourroukhin Y, Pletnikov M. Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. *Schizophr Res.* (2016) 176:72–82. doi: 10.1016/j.schres.2014.10.044
12. Duncan LE, Holmans PA, Lee PH, O’Dushaline CT, Kirby AW, Smoller JW, et al. Pathway analyses implicate glial cells in schizophrenia. *PLoS ONE* (2014) 9:e98441. doi: 10.1371/journal.pone.0098441
13. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FBSC. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. *Biochim Biophys. Acta* (1989) 1004:169–79. doi: 10.1016/0005-2760(89)90265-8
14. Hattingen E, Raab P, Franz K, Zanella FE, Lanfermann H, Pilatus U. Myo-inositol: a marker of reactive astrogliosis in glioma tumor? *NMR Biomed.* (2008) 21:233–41. doi: 10.1002/nbm.1186
15. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. *Dev Neurosci.* (1993) 15:289–98. doi: 10.1159/000113347
16. Griffon JI, Bollard M, Nicholson J, Bhakoo K. Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. *NMR Biomed.* (2002) 15:375–84. doi: 10.1002/nbm.792
17. Filibian M, Frasca A, Maggioni D, Micotti E, Vezzani A, Ravizza T. In vivo imaging of glia activation using 1H-magnetic resonance spectroscopy to detect putative biomarkers of tissue epileptogenicity. *Epilepsia* (2012) 53:1907–16. doi: 10.1111/j.1528-1167.2012.03685.x
18. Rothermundt M, Ohmann P, Abel S, Siegmund A, Pedersen A, Ponath G, et al. Giall cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. *Prog Neuro-Psychopharmacol Biol Psychiat.* (2007) 31:361–4. doi: 10.1016/j.pnpbp.2006.09.013
19. Geisler PC, Ugun-Klusek A, Lawler K, Pardon M-C, Yuchun D, Bai L, et al. Dynamic metabolic patterns tracking neurodegeneration and gliosis following 265 proteasome dysfunction in mouse forebrain neurons. *Sci Rep.* (2018) 8:4833. doi: 10.1038/s41598-018-23155-2
20. Pardon M-C, Yanez Lopez M, Yuchun D, Marijanska M, Prior M, Brignell C, et al. Magnetic resonance spectroscopy discriminates the response to microglial stimulation of wild type and Alzheimer’s disease models. *Sci Rep.* (2016) 6:19880. doi: 10.1038/srep19880
21. Harris IL, Choi I-Y, Brooks WM. Probing astrocyte metabolism in vivo: proton magnetic resonance spectroscopy in the injured and aging brain. *Front Aging Neurosci.* (2015) 7:202. doi: 10.3389/fnagi.2015.00202
22. Kierans AS, Kirov II, Goen O, Haemer G, Nisenbaum E, Babb JS, et al. Myo-inositol and glutamate complex neurometabolite abnormality after mild traumatic brain injury. *Neurology* (2014) 82:521–8. doi: 10.1212/wnl.00000000000105
23. Kim H, McGrath BM, Silverstone PH. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cyle) to psychiatric disorders–focus on magnetic resonance spectroscopy (MRS) studies. *Hum Psychopharmacol.* (2009) 25:309–26. doi: 10.1002/hup.693
24. Schwark A, Alves FDS, Pouwels PJW, van Alenwoosta T. Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies. *J Neurochem.* (2014) 128:1–87. doi: 10.1111/jn.12398
25. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
26. Vogt BA, Nimchinsky EA, Vogt LJ, Hof P. Human cingulate cortex: surface features, flat maps, and cytoarchitecture. *J Compar Neurol.* (2004) 359:490–506. doi: 10.1002/cne.93390310
27. Egerton A, Modinos G, Ferrera D, McGuire P. Neuroimaging studies of GABA and glutamatergic neurotransmission in schizophrenia: a systematic review with meta-analysis. *Transl Psychiatry.* (2017) 7:e1147. doi: 10.1038/tp.2017.124
28. Rowland LM, Summerfelt A, Wijtenburg SA, Du X, Chiappelli JJ, Krishna N, et al. Frontal glutamate and γ-aminobutyric acid levels and their associations with mismatch negativity and digit sequencing task performance in schizophrenia. *JAMA Psychiatry.* (2016) 73:166–74. doi: 10.1001/jamapsychiatry.2015.2680
29. Wijtenburg SA, Wright SN, Korenic SA, Gaston FE, Ndubuizu N, Chiappelli J, et al. Altered glutamate and regional cerebral blood flow levels in schizophrenia: A1H-MRS and pCASL study. *Neuropsychopharmacology* (2017) 42:562–71. doi: 10.1038/s41386-017-00152-y
30. Delamillieure P, Fernandez J, Constans J-M, Brazo P, Abadié P, et al. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. *Am J Psychiatry* (2000) 157:641–3. doi: 10.1176/appi.ajp.157.4.641
31. Thébierge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malia AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. *Br J Psychiatry* (2007) 191:325–34. doi: 10.1192/bjp.bp.106.033670
32. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. *Biol Psychiatry* (2014) 75:e11–13. doi: 10.1016/j.biopsych.2013.06.011

33. Viechbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw.* (2010) 36:41–48. doi: 10.18637/jss.v036.i03

34. Brandt AS, Unschuld PG, Pradhan S, Lim IAL, Churchill G, Harris AD, et al. Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a (1)H MRS Study at 7T. *Schizophr Res.* (2016) 172:101–5. doi: 10.1016/j.schres.2016.02.017

35. Bustillo JR, Chen H, Jones T, Lemke N, Abbott C, Qualls C, et al. Increased glutamate in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. *JAMA Psychiatry* (2014) 71:265–72. doi: 10.1001/jamapsychiatry.2013.3939

36. Chiappelli J, Rowland LM, Wijtenburg SA, Muellerklein F, Tagamets M, McMahon RP, et al. Evaluation of myo-inositol as a potential biomarker for depression in schizophrenia. *Neuropsychopharmacology* (2015) 40:2157–64. doi: 10.1038/npp.2015.57

37. Chiu PW, Lui SYH, Hung KSY, Chan RCK, Chan Q, Sham PC, et al. In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: a proton magnetic resonance spectroscopy study. *Schizophr Res.* (2017) 193:295–303. doi: 10.1016/j.schres.2017.07.021

38. Delamillieure P, Constans J-M, Fernandez J, Bravo P, Benali K, Courtieux P, et al. Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. *Schizophr Bull.* (2002) 28:329–39. doi: 10.1093/oxfordjournals.schbul.a06942

39. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO, et al. Proton MRS in twins pair discordant for schizophrenia. *Mol Psychiatry* (2010) 15:308–18. doi:10.1038/mp.2008.87

40. Öngür D, Prescott AP, McCarthy J, Cohen BM, Renshaw PF. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. *Biol Psychiatry* (2010) 68:667–70. doi: 10.1016/j.biopsych.2010.05.016

41. Öngür D, Jensen JE, Prescott AP, Stork C, Lundy M, Cohen BM, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. *Biolog Psychiatry* (2008) 64:718–26. doi: 10.1016/j.biopsych.2008.05.014

42. Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. *Biol Psychiatry* (2010) 68:625–33. doi: 10.1016/j.biopsych.2010.04.013

43. Rowland LM, Pradhan S, Korenic S, Wijtenburg SA, Hong LE, Eddean RA, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy at 3 T. *JAMA Psychiatry* (2015) 72:805–18. doi: 10.1001/jamapsychiatry.2015.5080

44. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RWJ, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. *Schizophr Res.* (2002) 57:127–38. doi: 10.1016/S0920-9964(02)00339-0

45. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. *Cereb Cortex* (2002) 12:386–94. doi: 10.1093/cercor/12.4.386

46. Rajkowska G, Miguel-Hidalgo JI, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. *Biol Psychiatry* (2015) 77:305–18. doi: 10.1016/j.biopsych.2015.03.019

47. Yasukawa R, Miyaoka T, Mizuno S, Inagaki T, Horiguchi J, Oda K, et al. Neurometabolites in schizophrenia and bipolar disorder – a systematic review and meta-analysis. *Psychiatry Res.* (2012) 203:111–25. doi: 10.1016/j.psychres.2012.02.003

48. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. *Am J Psychiatry* (2002) 159:1944–6. doi: 10.1176/ajp.159.11.1944

49. Yasukawa R, Miyaoka T, Mizuno S, Inagaki T, Horiguchi J, Oda K, et al. Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert’s syndrome). *J Psychiatry Neurosci.* (2005) 30:416–22.

50. Shimon H, Sobolye V, Davidson M, Haroutunian V, Belmaker RH, Agam G. Inositol levels are decreased in postmortem brain of schizophrenic patients. *Biol Psychiatry* (1998) 44:428–32. doi: 10.1016/S0006-3223(98)00071-7

51. Benes FM, Davidson J, Bird ED. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. *Arch Gen Psychiatry* (1986) 43:31–5. doi: 10.1001/archpsyc.1986.01800010330004

52. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. *Cereb Cortex* (2002) 12:386–94. doi: 10.1093/cercor/12.4.386

53. Rajkowska G, Miguel-Hidalgo JI, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. *Biol Psychiatry* (2015) 77:305–18. doi: 10.1016/j.biopsych.2015.03.019

54. Yasukawa R, Miyaoka T, Mizuno S, Inagaki T, Horiguchi J, Oda K, et al. Neurometabolites in schizophrenia and bipolar disorder – a systematic review and meta-analysis. *Psychiatry Res.* (2012) 203:111–25. doi: 10.1016/j.psychres.2012.02.003
Das et al. Myo-Inositol and Schizophrenia

70. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. *Neuroscience* (2013) 251:90–107. doi: 10.1016/j.neuroscience.2012.04.044
71. Dogan AE, Yüksel C, Du F, Chouinard V-A, Öngür D. Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies. *Neuropsychopharmacology* (2018) 43:1681–90. doi: 10.1038/s41386-018-0041-9
72. Shi D, Xu S, Waddell I, Scalfi S, Roys G, Gullapalli RP, et al. Longitudinal in vivo developmental changes of metabolites in the hippocampus of Fmr1 knockout mice. *J Neurochem.* (2012) 123:971–81. doi: 10.1111/jnc.12048
73. Plittman E, Fuente-Sandoval C de la, Reyes-Madrigal F, Cruz G, León-Ortiz P, et al. Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients with first-episode psychosis: a proton magnetic resonance spectroscopy study with implications for glial dysfunction. *Schizophr Bull.* (2015) 42:415–24. doi: 10.1093/schbul/bdv118
74. Auer DP, Wilke M, Grabner A, Heidenreich JG, Bronisch T, Wetter TC. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. *Schizophr Res.* (2001) 52:87–99. doi: 10.1016/S0920-9964(01)00155-4
75. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. *Biol Psychiatry* (2007) 62:1396–404. doi: 10.1016/j.biopsych.2007.05.025
76. Harwood AJ. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. *Mol Psychiatry* (2005) 10:117–26. doi: 10.1038/sj.mp.4001618
77. Konopaske GT, Dorph-Petersen K-A, Sweet RA, Pierri JN, Zhang W, Sampson AR, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. *Biol Psychiatry* (2008) 63:759–65. doi: 10.1016/j.biopsych.2007.08.018
78. Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarska B, Kubas M, et al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). *Pharmacopsychiatry* (2005) 38:214–9. doi: 10.1055/s-2005-873156
79. Bracken BK, Rouse ED, Renshaw PF, Olson DP. T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia. *Psychiatry Res.* (2013) 213:142–53. doi: 10.1016/j.psychres.2013.03.005
80. Öngür D, Prescott AP, Jensen JE, Rouse ED, Cohen BM, Renshaw PF, et al. T2 relaxation time abnormalities in bipolar disorder and schizophrenia. *Magn Reson Med.* (2010) 63:1–8. doi: 10.1002/mrm.22148
81. Williamson P, Pelz D, Merskey H, Morrison S, Karlík S, Drost D, et al. Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. *Am J Psychiatry* (1992) 149:549–51. doi: 10.1176/ajp.149.4.549
82. Li Q, Leung YO, Zhou I, Ho LC, Kong W, Basil P, et al. Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model. *Transl Psychiatry* (2015) 5:e641. doi: 10.1038/tp.2015.126
83. McNamara RK, Jandacek R, Tsu P, Weber W, Chu W-J, Strakowski SM, et al. Low docosahexaenoic acid status is associated with reduced indices in cortical integrity in the anterior cingulate of healthy male children: a 1H MRS Study. *Nutr Neurosci.* (2013) 16:183–90. doi: 10.1179/1476830512Y.0000000045
84. Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. *Hum Psychopharmacol.* (2014) 29:55–63. doi: 10.1002/hup.2369
85. Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, et al. Double-blind, controlled trial of inositol treatment of depression. *Am J Psychiatry* (1995) 152:792–4. doi: 10.1176/ajp.152.5.792
86. Levine J, Umansky R, Ezrielev G, Belmaker RH. Lack of effect of inositol treatment in chronic schizophrenia. *Biol Psychiatry* (1993) 33:673–5. doi: 10.1016/0006-3223(93)90112-Q
87. Firth J, Stubbs B, Sarris J, Rosenbaum S, Teasdale S, Berk M, et al. The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. *Psychol Med.* (2017) 47:1515–27. doi: 10.1017/S0033291717000022
88. Elberling TV, Danielsen ER, Rasmussen AK, Feldt-Rasmussen U, Waldemar G, Thomsen C. Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotrophic Graves’ disease. *Neurology* (2003) 60:142–5. doi: 10.1212/01.WNL.0000038911.07643.BF
89. Haris M, Cai K, Singh A, Harirhan H, Reddy R. In vivo mapping of brain myo-inositol. *Neuroimage* (2011) 54:2079–85. doi: 10.1016/j.neuroimage.2010.10.017
90. Howes OD, McCutcheon R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. *Transl Psychiatry* (2017) 7:e1024. doi: 10.1038/sptx.2016.278
91. Shawcross DL, Balata S, Olde Damink SWM, Hayes PC, Wardlaw TC. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. *Mol Psychiatry* (2005) 10:117–26. doi: 10.1038/sj.mp.4001618
92. Parker CA, Nabulsi N, Holden D, Lin S, Cass T, Labaree D, et al. Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain. *J Nucl Med.* (2014) 55:838–44. doi: 10.2967/jnumed.113.131854
93. Reid MA, Salibi N, White DM, Gawne TJ, Denney TS, Lahti AC. TT Proton magnetic resonance spectroscopy of the anterior cingulate cortex in first-episode schizophrenia. *Schizophr Bull.* (2018). doi: 10.1093/schbul/bsh190. [Epub ahead of print].

Conflict of Interest Statement: LP reports personal speaker/advisory fees from Otsuka Canada, Janssen Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Janssen Canada, Otsuka Canada outside the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Das, Dey, Sabesan, Javadzadeh, Théberge, Radua and Palaniyappan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.